Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Sells $22,828.70 in Stock

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Jack Phillips sold 26,545 shares of the stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $0.86, for a total transaction of $22,828.70. Following the sale, the chief executive officer now owns 129,726 shares in the company, valued at approximately $111,564.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jack Phillips also recently made the following trade(s):

• On Wednesday, April 17th, Jack Phillips sold 26,735 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $0.78, for a total transaction of $20,853.30.
• On Thursday, April 4th, Jack Phillips sold 15,887 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $0.88, for a total transaction of $13,980.56.
• On Thursday, February 1st, Jack Phillips sold 494 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $1.30, for a total transaction of $642.20.

Accelerate Diagnostics Trading Up 4.5 %

Shares of NASDAQ:AXDX opened at $0.77 on Friday. The firm’s 50 day moving average is $1.00 and its two-hundred day moving average is $3.20. Accelerate Diagnostics, Inc. has a 52 week low of $0.73 and a 52 week high of $11.90. The firm has a market capitalization of $16.68 million, a P/E ratio of -0.16 and a beta of 0.52.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on AXDX shares. William Blair restated an “outperform” rating on shares of Accelerate Diagnostics in a research note on Tuesday, April 2nd. Craig Hallum dropped their price target on shares of Accelerate Diagnostics from $2.00 to $1.00 and set a “hold” rating on the stock in a research note on Monday, April 1st. Finally, StockNews.com started coverage on shares of Accelerate Diagnostics in a research note on Friday, April 12th. They issued a “hold” rating on the stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Griffin Asset Management Inc. boosted its holdings in shares of Accelerate Diagnostics by 11.0% in the first quarter. Griffin Asset Management Inc. now owns 1,354,254 shares of the medical research company’s stock valued at $1,341,000 after acquiring an additional 134,530 shares in the last quarter. Tejara Capital Ltd bought a new position in shares of Accelerate Diagnostics in the third quarter valued at approximately $78,000. Sonora Investment Management Group LLC bought a new position in shares of Accelerate Diagnostics in the third quarter valued at approximately $63,000. TCI Wealth Advisors Inc. bought a new position in shares of Accelerate Diagnostics in the third quarter valued at approximately $337,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Accelerate Diagnostics by 31.8% in the second quarter. Geode Capital Management LLC now owns 655,906 shares of the medical research company’s stock valued at $531,000 after acquiring an additional 158,383 shares in the last quarter. 17.14% of the stock is currently owned by institutional investors.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.